Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Other Operating Expenses (2019 - 2021)

Historic Other Operating Expenses for Beam Therapeutics (BEAM) over the last 3 years, with Q1 2021 value amounting to -$1.2 million.

  • Beam Therapeutics' Other Operating Expenses rose 4355.68% to -$1.2 million in Q1 2021 from the same period last year, while for Dec 2021 it was -$1.2 million, marking a year-over-year increase of 9808.03%. This contributed to the annual value of -$61.8 million for FY2020, which is 184930.64% down from last year.
  • According to the latest figures from Q1 2021, Beam Therapeutics' Other Operating Expenses is -$1.2 million, which was up 4355.68% from -$54.7 million recorded in Q4 2020.
  • Over the past 5 years, Beam Therapeutics' Other Operating Expenses peaked at $2.9 million during Q3 2020, and registered a low of -$54.7 million during Q4 2020.
  • Moreover, its 3-year median value for Other Operating Expenses was -$1.3 million (2019), whereas its average is -$8.2 million.
  • The largest annual percentage gain for Beam Therapeutics' Other Operating Expenses in the last 5 years was 39245.67% (2020), contrasted with its biggest fall of 367761.9% (2020).
  • Over the past 3 years, Beam Therapeutics' Other Operating Expenses (Quarter) stood at -$1.5 million in 2019, then crashed by 3596.08% to -$54.7 million in 2020, then surged by 97.83% to -$1.2 million in 2021.
  • Its Other Operating Expenses stands at -$1.2 million for Q1 2021, versus -$54.7 million for Q4 2020 and $2.9 million for Q3 2020.